Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampion for Basal Thumb Joint Arthritis
NCT02762760Phase 1Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aspartyl-alanyl-diketopiperazine in osteoarthritis (OA) (2 arms), sponsored by Ampio Pharmaceuticals, Inc. Primary endpoint: Safety Evaluation at 4 weeks. Started May 2016; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02762760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762760.